Detalhe da pesquisa
1.
Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active site.
Nat Chem Biol
; 12(10): 815-21, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27526030
2.
The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand-dependent Cancer Models.
Cancer Res Commun
; 2(9): 914-928, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36922934
3.
Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: optimization of the aniline.
Bioorg Med Chem Lett
; 21(16): 4702-4, 2011 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21764307
4.
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.
Mol Cancer Ther
; 20(2): 238-249, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33273059
5.
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC).
J Med Chem
; 62(24): 11004-11018, 2019 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31710489
6.
Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.
Bioorg Med Chem Lett
; 18(24): 6486-9, 2008 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18986805
7.
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing.
Bioorg Med Chem Lett
; 18(24): 6369-73, 2008 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18996007
8.
Unusual reactivity of N-acyl imides: N-aroyl-1,2,4-dithiazolidine-3,5-diones as acyl isocyanate equivalents.
Org Biomol Chem
; 6(22): 4099-101, 2008 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-18972038
9.
Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides.
J Med Chem
; 61(23): 10767-10792, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30403352
10.
Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point.
J Med Chem
; 60(8): 3438-3450, 2017 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28376306
11.
Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).
J Med Chem
; 59(10): 4859-66, 2016 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27078757
12.
Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2.
J Med Chem
; 58(11): 4790-801, 2015 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25977981
13.
Novel and versatile synthesis of disubstituted 1,2-dihydro-1,2,4-triazol-3-ones.
Org Lett
; 15(23): 6078-81, 2013 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-24246051
14.
Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex.
J Cell Biol
; 190(1): 25-34, 2010 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-20624899
15.
Design of a potent, soluble glucokinase activator with excellent in vivo efficacy.
Bioorg Med Chem Lett
; 16(10): 2705-9, 2006 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16503142
16.
Discovery, synthesis and biological evaluation of novel glucokinase activators.
Bioorg Med Chem Lett
; 15(8): 2103-6, 2005 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15808477